Lloyd Klickstein, Versanis Bio CEO

A No­var­tis castoff drug gets new life at an At­las-backed start­up look­ing to blaze a trail in obe­si­ty

Af­ter decades of fail­ure, the obe­si­ty field is fi­nal­ly see­ing some ma­jor progress with the suc­cess of a sta­ble of GLP-1 di­a­betes drugs show­ing clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.